Heron Therapeutics 将来の成長
Future 基準チェック /06
Heron Therapeuticsは、55.4%と6%でそれぞれ年率55.4%で利益と収益が成長すると予測される一方、EPSはgrowで55.6%年率。
主要情報
55.4%
収益成長率
55.63%
EPS成長率
| Biotechs 収益成長 | 27.2% |
| 収益成長率 | 6.0% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 11 Aug 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Jul 10
HRTX: Patent Appeal Outcome Will Drive Prospects For Future Profitability
Heron Therapeutics' updated analyst price target of $2 reflects a reset in fair value expectations and a lower assumed future P/E multiple as analysts factor in the recent Cinvanti patent setback along with potential generic competition. Analyst Commentary Recent Street research on Heron Therapeutics highlights a sharp reset in expectations after the Cinvanti patent decision, with analysts reassessing both downside risk from generic competition and any potential upside from an appeal and execution on the existing portfolio.ナラティブ更新 • Jun 26
HRTX: Appeal Of Patent Ruling Will Shape Future Profitability Outlook
The analyst price target for Heron Therapeutics has been reduced from $4.75 to $3.00, as analysts factor in the recent Cinvanti patent setback, higher perceived risk, and lower projected profitability, despite a higher assumed future P/E multiple. Analyst Commentary Analyst views on Heron Therapeutics have shifted quickly following the Cinvanti patent decision, with several adjustments to ratings and price targets that reflect both legal risk and revenue concentration in this product.
ナラティブ更新 • Jun 12
HRTX: Patent Appeal Outcome Will Shape Future Pricing Opportunity
Heron Therapeutics' updated analyst price target has moved down from $4 to $2, as analysts factor in the recent court decision on Cinvanti patents, the potential for generic competition, and reduced assumptions for growth, profitability, and fair value, alongside a higher discount rate and P/E multiple. Analyst Commentary Recent street research around Heron Therapeutics reflects a clear reset in expectations after the court ruling on Cinvanti patents.
ナラティブ更新 • May 29
HRTX: Reaffirmed 2026 Guidance And Execution Focus May Support Future Upside
Analysts have trimmed their price target on Heron Therapeutics by $2 to reflect updated views on discount rates, expected revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent commentary on Heron Therapeutics centers on how updated assumptions for discount rates, revenue trajectories, margins and future P/E multiples feed into valuation.ナラティブ更新 • May 13
HRTX: Revised Profit Outlook And Discount Rate Could Support Future Upside
Analysts have reduced their price target on Heron Therapeutics by $2, citing updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E as the main factors behind the adjustment. Analyst Commentary Recent research points to a more cautious stance on valuation for Heron Therapeutics, with the latest $2 reduction in the price target linked to refreshed assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E levels.Seeking Alpha • Feb 18
Heron: Near The Bottom Of A Trading Range Despite Positives
Summary HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031. Read the full article on Seeking Alpha分析記事 • Feb 12
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Dec 16
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have had a really impressive month, gaining 27% after a shaky period...分析記事 • Nov 08
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) missed earnings with its latest third-quarter results, disappointing...ナラティブ更新 • Aug 15
Advanced Non-Opioid Therapies Will Transform The Pain Management Market
With both the discount rate and consensus revenue growth forecasts for Heron Therapeutics remaining stable, the consensus analyst price target has consequently held steady at $4.75 per share. What's in the News Reaffirmed Q1 2025 net revenue guidance of $153.0 million to $163.0 million.分析記事 • May 09
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders might have noticed that Heron Therapeutics, Inc. ( NASDAQ:HRTX ) filed its quarterly result this time last...
新しいナラティブ • Apr 29
ZYNRELEF Label Expansion And VAN Launch Will Broaden Medical Access
Expansion of ZYNRELEF labeling and VAN launch enhance market potential, operational efficiency, and revenue growth.分析記事 • Apr 18
Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 08
Heron Therapeutics: Four Horse Race Of Approved Therapies
Summary Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last "Hold" rating in November 2024. I will evaluate Heron's investment merits based on its full year and Q4 2024 earnings, reported on February 27, 2025. The analysis includes insights from Heron's earnings press release, conference call, 10-Q, and presentation. Heron has demonstrated a variety of successful outcomes, warranting a reassessment of its investment potential. Read the full article on Seeking Alpha分析記事 • Mar 01
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...分析記事 • Nov 13
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has fared very poorly over the last month, falling by a...分析記事 • Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • Aug 08
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...分析記事 • May 30
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Apr 16
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. The availability of a vial access needle form of Zynrelef might not come until late 2024, but offers an additional milestone for Zynrelef's expansion. Read the full article on Seeking Alpha分析記事 • Mar 15
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) investors will be delighted, with the company turning in some strong numbers...分析記事 • Feb 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have continued their recent momentum with a 27% gain in the last month...分析記事 • Dec 22
Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 161 | -11 | N/A | 1 | 2 |
| 12/31/2027 | 146 | -21 | N/A | 13 | 2 |
| 12/31/2026 | 148 | -25 | N/A | 22 | 2 |
| 6/30/2026 | 151 | -34 | -12 | -12 | N/A |
| 3/31/2026 | 151 | -31 | -21 | -20 | N/A |
| 12/31/2025 | 155 | -20 | -28 | -28 | N/A |
| 9/30/2025 | 155 | -14 | -31 | -30 | N/A |
| 6/30/2025 | 150 | -1 | -30 | -28 | N/A |
| 3/31/2025 | 149 | -8 | -24 | -22 | N/A |
| 12/31/2024 | 144 | -14 | -24 | -23 | N/A |
| 9/30/2024 | 138 | -28 | -10 | -8 | N/A |
| 6/30/2024 | 136 | -48 | -23 | -21 | N/A |
| 3/31/2024 | 132 | -81 | -45 | -43 | N/A |
| 12/31/2023 | 127 | -111 | -60 | -59 | N/A |
| 9/30/2023 | 123 | -120 | -100 | -99 | N/A |
| 6/30/2023 | 118 | -137 | -128 | -127 | N/A |
| 3/31/2023 | 114 | -151 | -129 | -128 | N/A |
| 12/31/2022 | 108 | -182 | -149 | -147 | N/A |
| 9/30/2022 | 98 | -217 | -156 | -155 | N/A |
| 6/30/2022 | 95 | -227 | -174 | -171 | N/A |
| 3/31/2022 | 90 | -232 | -209 | -205 | N/A |
| 12/31/2021 | 86 | -221 | -206 | -203 | N/A |
| 9/30/2021 | 86 | -228 | -216 | -211 | N/A |
| 6/30/2021 | 83 | -234 | -204 | -200 | N/A |
| 3/31/2021 | 83 | -228 | -198 | -194 | N/A |
| 12/31/2020 | 89 | -227 | -192 | -185 | N/A |
| 9/30/2020 | 103 | -223 | -167 | -159 | N/A |
| 6/30/2020 | 126 | -198 | -149 | -143 | N/A |
| 3/31/2020 | 140 | -193 | N/A | -108 | N/A |
| 12/31/2019 | 146 | -205 | N/A | -125 | N/A |
| 9/30/2019 | 140 | -196 | N/A | -131 | N/A |
| 6/30/2019 | 117 | -201 | N/A | -141 | N/A |
| 3/31/2019 | 98 | -190 | N/A | -179 | N/A |
| 12/31/2018 | 77 | -179 | N/A | -192 | N/A |
| 9/30/2018 | 59 | -192 | N/A | -205 | N/A |
| 6/30/2018 | 47 | -195 | N/A | -210 | N/A |
| 3/31/2018 | 39 | -199 | N/A | -181 | N/A |
| 12/31/2017 | 31 | -197 | N/A | -170 | N/A |
| 9/30/2017 | 22 | -183 | N/A | -162 | N/A |
| 6/30/2017 | 13 | -190 | N/A | -157 | N/A |
| 3/31/2017 | 5 | -190 | N/A | -152 | N/A |
| 12/31/2016 | 1 | -173 | N/A | -134 | N/A |
| 9/30/2016 | N/A | -156 | N/A | -119 | N/A |
| 6/30/2016 | N/A | -131 | N/A | -102 | N/A |
| 3/31/2016 | N/A | -110 | N/A | -91 | N/A |
| 12/31/2015 | N/A | -98 | N/A | -79 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: HRTX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: HRTX今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: HRTX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: HRTXの収益 ( 6% ) US市場 ( 12.9% ) よりも低い成長が予測されています。
高い収益成長: HRTXの収益 ( 6% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: HRTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/14 18:05 |
| 終値 | 2026/08/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Heron Therapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Joshua Schimmer | Evercore ISI |